Exelixis Inc - Company Profile
Powered by 
All the data and insights you need on Exelixis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Exelixis Inc Strategy Report
- Understand Exelixis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Exelixis Catalyst Calendar
Proactively evaluate Exelixis Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Exelixis Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Oct 2019 | Phase I Trial Completion | Exelixis Inc; Genentech USA Inc; H. Lee Moffitt Cancer Center & Research Institute Inc | EXEL | cobimetinib fumarate; vemurafenib; XL-888 | Oncology | Melanoma; Metastatic Melanoma; Skin Cancer | Clinical Trial Registry |
| 11 Oct 2019 | Phase III Trial Completion | Exelixis Inc; F. Hoffmann-La Roche Ltd | EXEL; ROG | atezolizumab; cobimetinib fumarate; vemurafenib | Oncology | Melanoma; Metastatic Melanoma; Solid Tumor | Company Press Release |
| 01 Oct 2019 | Phase I/II Trial Initiation | Exelixis Inc; University of Iowa | EXEL | Cabometyx; cabozantinib s-malate | Oncology | Melanoma; Metastatic Melanoma | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer